Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study-Reference-Cited by-同舟云学术

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study

Published:2017-05-04 Issue:3 Volume:19 Page:e12696
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Forns Xavier¹,Berenguer Marina²,Herzer Kerstin³,Sterneck Martina⁴,Donato Maria Francesca⁵,Andreone Pietro⁶,Fagiuoli Stefano⁷,Cieciura Tomasz⁸,Durlik Magdalena⁹,Calleja Jose Luis¹⁰,Mariño Zoe¹,Shukla Umesh¹¹,Verbinnen Thierry¹²,Lenz Oliver¹²,Ouwerkerk-Mahadevan Sivi¹³,Peeters Monika¹²,Janssen Katrien¹²,Kalmeijer Ronald¹¹,Jessner Wolfgang¹¹

Affiliation:

1. Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD; University of Barcelona; Barcelona Spain

2. Department of Digestive Diseases, Hepatology and Liver Transplantation Unit; La Fe University Hospital and CIBEREHD; Valencia Spain

3. Department of General, Visceral and Transplantation Surgery and Department of Gastroenterology and Hepatology; University Hospital Essen; University Duisburg-Essen; Essen Germany

4. Department of Hepatobiliary and Transplant Surgery; University Medical Center Hamburg-Eppendorf; Hamburg Germany

5. Division of Digestive Diseases; IRCCS Maggiore Hospital; Milan Italy

6. Department of Medical and Surgical Sciences; University of Bologna; Bologna Italy

7. Gastroenterology and Transplant Hepatology; Papa Giovanni XXIII Hospital; Bergamo Italy

8. Department of Immunology, Transplant Medicine and Internal Diseases; Transplantation Institute; Medical University of Warsaw; Warsaw Poland

9. Department of Transplantation Medicine and Nephrology; Transplantation Institute; Medical University of Warsaw; Warsaw Poland

10. Liver Unit; Hospital Universitario Puerta de Hierro, CIBEREHD and IDIPHIM; Madrid Spain

11. Janssen Research & Development; LLC; Titusville NJ USA

12. Janssen Pharmaceutica NV; Beerse Belgium

13. Janssen Research & Development; Beerse Belgium

Funder

Janssen

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tid.12696/fullpdf

Reference31 articles.

1. Liver transplantation and hepatitis C;Rubin;Clin Res Hepatol Gastroenterol,2011

2. Hepatitis C virus kinetics during and immediately after liver transplantation;Garcia-Retortillo;Hepatology,2002

3. Hepatitis C recurrence: The Achilles heel of liver transplantation;Howell;Transpl Infect Dis,2014

4. Liver transplantation in the setting of chronic HCV;Terrault;Best Pract Res Clin Gastroenterol,2012

5. Recurrence of hepatitis C after liver transplantation;Vinaixa;Ann Gastroenterol,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EFFICACY OF SOFOSBUVIR AND DACLATASVIR IN COMPENSATED CHRONIC HEPATITIS C INFECTION: A SINGLE CENTER, OPEN-LABEL AND PROOF OF CONCEPT STUDY;GLOBAL JOURNAL FOR RESEARCH ANALYSIS;2021-03-15

2. Interactions between anti‐infective agents and immunosuppressants—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice;Clinical Transplantation;2019-04-23

3. Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis;Transplant Infectious Disease;2019-01-21

4. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN);Digestive and Liver Disease;2018-11

5. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN);Internal and Emergency Medicine;2018-09-25